For US Healthcare Professionals Only
Prescribing Information& Medication Guide Patient Site
Access and resources
Vafseo is approved for the TDAPA effective January 1, 2025
The Centers for Medicare & Medicaid Services (CMS) approved Vafseo for the Transitional Drug Add-on Payment Adjustment (TDAPA) under the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS).
About the TDAPA
- Under the TDAPA, CMS adjusts the bundled payment to providers for dialysis services by adding an amount for the cost of certain new renal dialysis drugs and biological products used in dialysis services
- The TDAPA adjustment applies for patients covered under the Medicare ESRD PPS and continues for 2 years until December 31, 2026
- The TDAPA helps dialysis organizations integrate innovative therapies into their treatment protocols to allow adoption of these products
Post-TDAPA, Akebia is committed to competitive pricing to ensure access to Vafseo for patients in need.
Discover upcoming educational programs
Join live or virtual sessions led by clinical experts and peers.
Learn about Vafseo and appropriate patient types
-
Download the Efficacy and Safety Brochure -
Download the Vafseo Dialysis Patient Profile -
Download the High ESA Dose Dialysis Patient Profile -
Download the Vafseo Peritoneal Dialysis Patient Profile
Getting started with Vafseo
-
Download the Ordering Guide -
Download the Billing and Coding Guide -
Download the Vafseo Dosing Checklist -
Download the Vafseo Dosing Guide -
Download the Baseline ESA Brochure
Resources for anemia managers
Explore key insights about Vafseo from our experts
Frequently asked questions
Get the answers you need to support your patients’ journey
Approximately 35% of patients experienced a decrease in Hb levels of 0.5 g/dL or more at week 4 in the Prevalent Dialysis Trial* - especially in those previously maintained on high doses of ESAs (≥300 U/kg/week of IV epoetin equivalent unit).5,6,†
The mean Hb for the study population began to rise by week 8.4,†
By week 12, more than half of patients were taking 450 mg or 600 mg.6,†,‡
It’s important to anticipate a potential dip, which may serve as an opportunity to review dosing and titration, consistent with the Vafseo Prescribing Information.
Vafseo has been approved for the TDAPA January 1, 2025.
Akebia Therapeutics Inc. does not guarantee payment or coverage for any product or service. The provider should contact patients’ payers directly for any revised or additional requirements, information, or guidance. It is always the provider’s responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, and payment policies.
EPO=erythropoietin; ESA=erythropoiesis-stimulating agent; Hb=hemoglobin; HIF-PHI=hypoxia-inducible factor prolyl hydroxylase inhibitor.
WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS
THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS.
VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE).
Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels.
No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks.
Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions.
CONTRAINDICATIONS
- Known hypersensitivity to VAFSEO or any of its components
- Uncontrolled hypertension
WARNINGS AND PRECAUTIONS
- Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular AccessA rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis.
- HepatotoxicityHepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease.
- HypertensionWorsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed.
- SeizuresSeizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency.
- Gastrointestinal (GI) ErosionGastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present.
- Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on DialysisThe safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa.
- MalignancyVAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies.
ADVERSE REACTIONS
- The most common adverse reactions (occurring at ≥ 10%) were hypertension and diarrhea.
DRUG INTERACTIONS
- Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron.
- Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders.
- BCRP substrates: Monitor for signs of substrate adverse reactions and consider dose reduction.
- Statins: Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg.
USE IN SPECIFIC POPULATIONS
- Pregnancy: May cause fetal harm. A pregnancy exposure registry is available to monitor outcomes in women exposed to VAFSEO during pregnancy. Report pregnancies to 1-844-445-3799.
- Lactation: Breastfeeding not recommended until two days after the final dose.
- Hepatic Impairment: Not recommended in patients with cirrhosis or active, acute liver disease.
VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Limitations of Use
- VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
- VAFSEO is not indicated for use:
- As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
- In patients with anemia due to CKD not on dialysis.
Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide.
